FIELD: medicine.
SUBSTANCE: subjects 1 and 2 are a pharmaceutical composition of pembrolizumab for the treatment of malignant neoplasm or infectious disease, containing: 5-50 mg/ml pembrolizumab; 0.087-0.432 mg/ml histidine; 0.464-0.931 mg/ml histidine hydrochloride monohydrate; 1-2 mg/ml glycine; trehalose 70-130 mg/ml and poloxamer 188 0.8-1.2 mg/ml or proline 20-34 mg/ml; and water for injection up to 1 ml, as well as obtained by lyophilization of the specified composition. Subjects 3 and 4 are using the pharmaceutical composition of pembrolizumab for the treatment of a malignant neoplasm or an infectious disease and for obtaining a drug. EFFECT: stability of the pharmaceutical composition of pembrolizumab and the preservation of the activity of the protein molecule in the composition.
26 cl, 6 dwg, 34 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF | 2022 |
|
RU2826886C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS | 2022 |
|
RU2821530C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| STABLE COMPOSITION OF ANTIBODY SPECIFICALLY BOUND WITH HER2 RECEPTORS AND PREPARATION METHOD THEREOF | 2014 |
|
RU2589691C2 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
